The Senate on Thursday unanimously passed a bill aimed at limiting the number of patents drugmakers can introduce and making it easier for generic and biosimilar competitors to enter the market.
Tag Archive for: generic drugs
Mylan and several major drugmakers such as Israel’s Teva Pharmaceutical Industries and India’s Sun Pharmaceutical Industries have been under the DOJ’s scanner for more than eight years over alleged anticompetitive business practices in fixing prices of certain generic drugs.
The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Here are some strategies company are employing to manage the drop in revenue.
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are developing at least 15 generic versions of its diabetes drug Ozempic and weight loss treatment Wegovy, clinical trial records showed.
Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven by increasing generic competition for its ADHD treatment Vyvanse.
The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex.
Generic drugs present a notable absence of consensus among physicians within the realm of healthcare regarding patients’ choice between branded and generic alternatives. This lack of a clear stance among healthcare providers prompts an in-depth investigation into the myriad factors shaping their perspectives, including efficacy, patient preferences, and cost considerations.
Resilience of global supply chains was heavily tested during the COVID pandemic. Several processes were enhanced to address unforeseen exigencies, and mitigation strategies were re-assessed. The recent conflict has, however, brought in a renewed sense of urgency.
A group of major pharmaceutical companies want an appeals court to force Connecticut and other states to remain in a coordinated legal proceeding over generic drug pricing, arguing that allowing them to pursue their claims separately would upend years of legal work and cause delays.
Despite a patent extension, Merck’s muscle relaxant reversal injection is now facing potential generic competition from Hikma Pharmaceuticals, which is seeking the FDA’s approval for a copycat version.